ReviewTranslational lung cancer research2023
Targeting lung cancer brain metastases: a narrative review of emerging insights for anaplastic lymphoma kinase (
Review in Translational lung cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 17 citations in OpenAlex.
- Genomic Analysis and Clinical Correlation of Non-Small Cell Lung Cancer with Special Reference to Brain Metastasis.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Article
- Brain metastases from non-small cell lung cancer: molecular subtypes and emerging CNS-directed precision therapies.Frontiers in oncology · 2026Review
- Physiologically based pharmacokinetic model of two ALK inhibitors to inform drug and dosing regimens for brain metastasis patients.Frontiers in pharmacology · 2026Article
- Anatomically Precise Microsurgical Resection of a Posterior Fossa Cerebellar Metastasis in an Elderly Patient with Preservation of Venous Outflow, Dentate Nucleus, and Cerebrospinal Fluid Pathways.Diagnostics (Basel, Switzerland) · 2025Article
- Oncologists' preferences for first-line treatment of ALK-positive metastatic NSCLC in the United States: a discrete choice experiment.Future oncology (London, England) · 2025Article
- Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases.Medical sciences (Basel, Switzerland) · 2025Review
- Site-Specific Inflammatory Signatures in Metastatic NSCLC: Insights from Routine Blood Count Parameters.Medicina (Kaunas, Lithuania) · 2025Article
- Classifying brain metastases originating from different pathological subtypes of lung cancer via a multimodal magnetic resonance imaging-based deep learning approach.Journal of thoracic disease · 2025Article
- Immunotherapy in lung cancer brain metastases.NPJ precision oncology · 2025Review
- Epidemiological, pathological, and molecular characteristics of lung cancer in Casablanca, Morocco: a retrospective study.The Pan African medical journal · 2025Article
- Coexistence of acute severe leukocytosis and anaplastic lymphoma kinase‑positive histiocytic sarcoma, a rare entity with an unusual presentation: A case report.Oncology letters · 2024Article
- Serum tumor markers and outcomes in lung cancer patients with brain metastases: a retrospective longitudinal cohort study.Translational lung cancer research · 2024Article
- Proceedings from the First Onco Summit: LATAM Chapter, 19-20 May 2023, Rio de Janeiro, Brazil.Cancers · 2024Article
- Preclinical evaluation of targeted therapies for central nervous system metastases.Disease models & mechanisms · 2024Review
- From pre-clinical to translational brain metastasis research: current challenges and emerging opportunities.Clinical & experimental metastasis · 2024Review
- Current opportunities and challenges in ALK-positive lung cancer.Translational lung cancer research · 2024Article
- Management strategies for intracranial progression in ALK-positive non-small cell lung cancer: a real-world cohort study.Journal of neuro-oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Background and Objective: Lung cancer is commonly associated with brain metastasis formation, and certain subtypes, such as anaplastic lymphoma kinase ( Methods: Review of PubMed and Google Scholar databases as well as ClinicalTrials.gov provided background and seminal trials for the local and systemic management of Key Content and Findings: The development of effective, CNS-penetrant systemic agents-including alectinib, brigatinib, ceritinib, and lorlatinib-has dramatically changed the management and prevention of Conclusions: Novel targeted therapies offer patients a pathway to delay, obviate, or supplement traditional local therapies while minimizing neurologic sequelae of treatment and may reduce the risk of brain metastasis formation. However, the selection of patients to whom local and targeted treatments is offered is not trivial, and the risks and benefits of both must be weighed carefully. More work is needed to establish treatment regimens that yield durable intra- and extracranial disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.